| Característica |
Objectiu de la convocatòria
These grants are strictly for clinical research with human subjects who have Fragile X.
|
Característiques principals
Priority will be given to clinical trials of potentially disease-modifying agents that have been previously validated in Fragile X animal models, particularly those supported by prior FRAXA-funded research. Other types of clinical studies, such as biomarker research in Fragile X patients or trials of symptomatic therapies, will also be considered but are of lower priority.
No limit to structure of grant (can fund PI, postdoc, grad student, technician, supplies, etc.) or time-frame (though all grants over one year still need yearly renewal).
No limit on amount, but please remember that applications are evaluated based on relative value, so smaller requests have an advantage.
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact:
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: [email protected] Ext.: 1670
Marta López: [email protected] Ext.: 1576
|
Convocatòria (URL)
https://www.fraxa.org/fragile-x-research/grant-application/
|
Informació addicional
Applications are accepted on a rolling basis.
|
Documentació
Please email your application as a single pdf to both [email protected] and [email protected] providing the following information:
Project title
Lay description suitable for publishing on fraxa.org if project is funded
Requested start date. The earliest possible start date is 4 months after receipt of the application
Budget
Scientific Description of the proposed project (8-15 pages recommended)
Curriculum Vitae for the Principal Investigator
Curriculum Vitae for the Fellow and/or other personnel to be supported under the grant
Three references who are willing to be contacted to provide recommendations for candidate fellow
Full accounting of any other current and submitted sources of support for this project and other lab research
|
Dotació i durada
Flexible in amount, structure, and duration, but may be subject to some negotiation.
|